☆ 4.7 Article

Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy

RHEUMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial

Andrew L Mammen et al.

Lancet Rheumatology (2023)

Add to Collection

Article Pharmacology & Pharmacy

Efgartigimod: First Approval

Young-A Heo

Summary: Efgartigimod is a novel drug developed by argenx for the treatment of autoimmune diseases, including myasthenia gravis. It received its first approval in the USA in 2021 and is currently being evaluated and registered in other countries. Numerous clinical studies are also investigating the use of Efgartigimod in various other autoimmune diseases.

DRUGS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model

Sarah Julien et al.

Summary: In a humanized mouse model of IMNM, early administration of zilucoplan was found to prevent the onset of myopathy and significantly inhibit complement activation.

BIOMEDICINES (2022)

Add to Collection

Review Rheumatology

Immune-mediated necrotizing myopathy: clinical features and pathogenesis

Yves Allenbach et al.

NATURE REVIEWS RHEUMATOLOGY (2020)

Add to Collection

Article Rheumatology

In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy

Cecile Bergua et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Article Clinical Neurology

Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement

Yves Allenbach et al.

NEUROLOGY (2018)

Add to Collection

Article Medicine, Research & Experimental

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Add to Collection

Article Clinical Neurology

Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase Antibodies in Necrotizing Myopathies: Myofiber Atrophy and Impairment of Muscle Regeneration in Necrotizing Autoimmune Myopathies

Louiza Arouche-Delaperche et al.

ANNALS OF NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy

Charles D. Kassardjian et al.

JAMA NEUROLOGY (2015)

Add to Collection

Article Rheumatology

Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies

Laurent Drouot et al.

ARTHRITIS RESEARCH & THERAPY (2014)

Add to Collection

Article Immunology

Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies

Lucile Musset et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2014)

Add to Collection

Article Rheumatology

Antibody Levels Correlate With Creatine Kinase Levels and Strength in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase-Associated Autoimmune Myopathy

Jessie L. Werner et al.

ARTHRITIS AND RHEUMATISM (2012)

Add to Collection

Review Immunology

FcRn: the neonatal Fc receptor comes of age

Derry C. Roopenian et al.

NATURE REVIEWS IMMUNOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.